LDE225 (NVP-LDE225) is a potent, selective and orally bioavailable Smoothened (SMO) antagonist that inhibits hedgehog (Hh) signaling pathway via antagonism of the Smoothened receptor (SMO).
More Information Supplier PageLDE225 (NVP-LDE225) is a potent, selective and orally bioavailable Smoothened (SMO) antagonist that inhibits hedgehog (Hh) signaling pathway via antagonism of the Smoothened receptor (SMO).
More Information Supplier PageLBH589 is a hydroxamic acid and acts as a non-selective HDAC inhibitor with IC5o of HDAC1 to be 0.23 nM.
More Information Supplier PageLamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).
More Information Supplier PageLamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).
More Information Supplier PageLamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).
More Information Supplier PageLamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).
More Information Supplier PageLamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).
More Information Supplier PageLacosamide is a medication developed for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.
More Information Supplier PageLacosamide is a medication developed for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.
More Information Supplier Page
